Eton Pharma Q3 product sales +40% YoY, first positive GAAP net income from product sales

Eton Pharmaceuticals, Inc.

2024-Q3 EPS reported -$0.12 revenue$27,364,000

Total revenue $10.3M, net income $0.6M ($0.02 diluted EPS); prior year net loss $0.6M.
Product sales $9.8M, up 40% YoY and 8% sequentially; 15th straight quarter of sequential growth.
Entered asset purchase agreement to acquire Increlex from Ipsen, expected to close near year-end 2024 and be accretive to 2025 earnings.
FDA accepted ET-400 NDA with PDUFA date Feb 28, 2025; additional patent granted for ET-400 expiring 2043.
Cash $20.3M; generated $2.9M operating cash flow in Q3; expects positive Q4 cash flow and will fund Increlex with cash on hand and credit facility expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.